S-1/A: Ekso Bionics Announces Public Offering of Units and Warrants to Bolster Growth

Ekso Bionics is undertaking a firm commitment underwritten public offering of units and warrants to raise capital for general corporate purposes, including expansion and R&D.

Summary

• Ekso Bionics Holdings, Inc. is offering 5,530,973 units, each consisting of one share of common stock, one Series A warrant, and one Series B warrant, in a firm commitment underwritten public offering.
• The company is also offering pre-funded units to investors whose purchase would result in exceeding a 4.99% or 9.99% ownership threshold.
• Each pre-funded unit includes a pre-funded warrant, one Series A warrant, and one Series B warrant.
• The purchase price of each pre-funded unit will be the unit price minus $0.001, with a pre-funded warrant exercise price of $0.001 per share.
• The common stock is listed on The Nasdaq Capital Market under the symbol EKSO, with the last reported sale price on August 27, 2024, at $1.13 per share.
• The company estimates net proceeds of approximately $5.3 million from the offering, based on an assumed offering price of $1.13 per unit.
• The proceeds are intended for general corporate purposes, including growth of the EksoHealth segment, research and development, and potential acquisitions.

Sentiment

Score: 4

Explanation: The announcement is a mixed bag. While the capital raise is intended to fuel growth, the offering terms are dilutive and the company faces significant risks. The sentiment is cautiously negative.

Positives

• The offering aims to provide capital for growth and expansion of the EksoHealth segment, particularly following Medicare CMS reimbursement of the Ekso Indego Personal device.
• Funds will also support research and development activities, potentially leading to enhanced product offerings.
• The company may pursue strategic initiatives, including synergistic and accretive acquisitions.

Negatives

• There is no established trading market for the Series A Warrants, the Series B Warrants or the pre-funded warrants, which limits liquidity.
• Investors will experience immediate dilution in the book value per share of the common stock they purchase.
• The company has a history of losses and may not achieve or maintain profitability.

Risks

• The markets for Ekso Bionics' products are highly competitive and continue to develop.
• The company may not be able to reduce manufacturing or service costs as planned.
• Shortages in materials or reductions in manufacturer capacity could impact future results.
• Changes in coverage policies and reimbursement levels of third-party payers may affect sales.
• The company may face difficulties in acquiring and integrating other companies or technologies.
• The company may not be able to enhance product offerings through research and development.
• The company has incurred significant losses and anticipates continuing to incur losses.
• The loan agreement with Pacific Western Bank imposes financial and operational restrictions.
• Protecting intellectual property rights can be costly and uncertain.
• Failure to obtain or maintain regulatory clearances or approvals could harm commercial operations.
• Modifications to products may require new clearances or approvals.
• Failure to meet post-market regulatory requirements could result in fines or facility closures.
• The company's success depends on its management team and its ability to hire, train, and retain employees.

Future Outlook

The company intends to use the net proceeds from this offering for general corporate purposes, which may include growth and expansion of our EksoHealth segment as we work to increase our revenue following the establishment of Medicare CMS reimbursement of the Ekso Indego Personal device, research and development activities, selling, general and administrative costs, and pursuing strategic initiatives, which initiatives may include potential synergistic and accretive acquisitions, as well as meeting our other working capital needs.

Industry Context

The announcement comes as the market for exoskeleton products is developing and becoming increasingly competitive. The company highlights its focus on the Enterprise Health business line and the recent Medicare reimbursement approval as key drivers for future growth.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• Employees may benefit from increased investment in R&D and company growth.
• Customers may see improved product offerings and services.
• Suppliers and creditors may benefit from the company's strengthened financial position.

Next Steps

• The underwriter expects to deliver the shares, Series A Warrants, Series B Warrants and pre-funded warrants to purchasers on or about , 2024.
• The company will apply to list or quote all of the Shares on the Trading Market and promptly secure the listing of all of the Shares on the Trading Market.

Key Dates

Keywords

public offering, warrants, exoskeleton, ekso bionics, eksohealth, ekso, securities, units, common stock, pre-funded